Same Price & Trial Data: Scotland OKs Spravato Funding After England Says No
Executive Summary
Discrepancy in access to Janssen’s antidepressant nasal spray between patients in Scotland and those in England and the rest of the UK may be due to the differences in methodologies and approaches used by the health technology assessment bodies.
You may also be interested in...
Janssen to Address NICE's Concerns Following Another English Funding No For Spravato
UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.
European CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: